Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Damascus University
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04727684CT.gov Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI | — | Completed | — | — | — |
NCT04727671CT.gov Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients. | — | Completed | — | — | — |
NCT02478775CT.gov Dysregulation of FSH in Obesity: Functional and Statistical Analysis | — | Completed | — | — | — |
NCT01421095CT.gov Ovarian Reserve Testing in Female Young Adult Cancer Survivors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Infertility Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Fsh (this asset) | Damascus University | Approved | BB · 71 |
| Clomiphene Citrate | Sana'a University | P4 | A |
| Metformin | Peking University Third Hospital | P4 | A |
| Letrozole | GABRIEL MONTEIRO PINHEIRO | P4 | BBB |
| Cetrotide | Fayoum University | P4 | BBB |
| Human Chorionic Gonadotropin | Damascus University | P4 | BBB |
| Follitropin Beta | Ferring Pharmaceuticals | P4 | BBB |
| Urofollitropin | Mansoura Integrated Fertility Center | P4 | BBB |
| Human Menopausal Gonadotropin | Damascus University | P4 | BB |
+35 more in the Infertility Disorder cohort
Other indications for Recombinant Fsh
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | P4 | BB · 65 |
| Anovulation | — | N/A | D · 30 |
| Cancer | — | N/A | D · 28 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant Fsh in Infertility Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-fsh-infertility-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →